CClinicalTrials.gg
Sign In
Status unknownNCT04026724RCSCD-TCMUpdated Jul 22, 2019

Retrospective Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine

An observational study in Atherosclerotic Heart Disease With Angina Nos, sponsored by Tianjin University of Traditional Chinese Medicine. Status unknown at 1 site in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-22.

Sponsored by Tianjin University of Traditional Chinese Medicine · Observational

The sponsor has not verified this record recently (last verified Jul 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
12,400
Ages
35 Years to 75 Years
Sex
All
01

Study summary

A retrospective cohort study was performed in patients with angina pectoris who were treated with oral Chinese patent medicine and Western medicine.The hospital's medical record management system was used to collect symptoms of angina pectoris, dose and frequency of nitroglycerin use, clinical biochemical test and imaging examination.To explore the clinical efficacy of Chinese patent medicine in the treatment of coronary heart disease with angina pectoris, and provide reliable data support for its clinical application.

02

Conditions studied

  • Atherosclerotic Heart Disease With Angina Nos
03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's planned enrollment of 12,400 is above the median of 294 across 1,241 observational studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Tianjin University of Traditional Chinese Medicine is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The collaboration network of coronary heart disease research medical units formed by the research group, including the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin Nankai Hospital, Tianjin Chest Hospital, Tianjin Medical University General Hospital, a total of 5 hospitals.

Inclusion criteria

  1. Age 35-75 years old, gender is not limited;
  2. Admission time is September 1, 2014 - September 1, 1919;
  3. Patients with coronary heart disease and angina pectoris in the Department of Cardiology or Outpatient Department, the diagnosis of angina pectoris meets the diagnostic criteria of Western medicine and the standard of TCM syndrome differentiation;
  4. Patients who met the criteria for drug treatment, the exposed group was treated with traditional Chinese medicine combined with Western medicine, and the non-exposed group was treated with Western medicine alone.

Exclusion criteria

Exclusion Criteria:

  1. Combined with other heart diseases, neurosis, menopausal syndrome, hyperthyroidism, cervical or vertebral artery type cervical spondylosis, gastro-oesophageal reflux disease or esophageal hiatus hernia may cause chest pain;
  2. patients with acute myocardial infarction, heart failure, myocarditis, cardiomyopathy, severe heart valve disease, liver failure or renal failure, malignant tumors and severe metabolic diseases, as well as patients with severe symptoms and uncontrollable angina;
  3. Pregnant women, lactating women or women of childbearing age who have birth requirements;
  4. Mental patients, or cognitive dysfunction;
  5. The investigator believes that there are other situations that are not suitable for the trial.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
12,400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Exposed group

    Chinese patent medicine combined with western medicine routine treatment

    Drug: Chinese patent medicine

  • Non-exposed group

    Western medicine routine treatment

Interventions

  • DrugChinese patent medicine

    Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.

06

What researchers measure

Primary outcomes

  1. Symptoms of angina

    Time frame: one year

  2. Dosage and frequency of use of nitroglycerin

    Time frame: one year

  3. Clinical biochemical indicators test

    Time frame: one year

  4. Film degree exam

    Time frame: one year

07

Study locations

1 site
  • Tianjin University of Traditional Chinese Medicine
    Tianjin, Tianjin 300193, China
08

References and documents

Publications

  • Wang J, Huang X, Fu C, Sheng Q, Liu P. Association between triglyceride glucose index, coronary artery calcification and multivessel coronary disease in Chinese patients with acute coronary syndrome. Cardiovasc Diabetol. 2022 Sep 16;21(1):187. doi: 10.1186/s12933-022-01615-4. PubMed 36114495 ↗
  • Yu L, Li Z, Yang R, Pan G, Cheng Q, He Y, Liu Y, Liu F, Ma M, Yang T, Wang Y, Su J, Zheng Y, Gao S, Xu Q, Li L, Yu C. Impaired Sensitivity to Thyroid Hormones Is Associated With Elevated Blood Glucose in Coronary Heart Disease. Front Endocrinol (Lausanne). 2022 Jun 15;13:895843. doi: 10.3389/fendo.2022.895843. eCollection 2022. PubMed 35784545 ↗
  • Su J, Li Z, Huang M, Wang Y, Yang T, Ma M, Ni T, Pan G, Lai Z, Li C, Li L, Yu C. Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovasc Diabetol. 2022 Jun 6;21(1):96. doi: 10.1186/s12933-022-01523-7. PubMed 35668496 ↗

Individual participant data

Plan to share: Yes

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04026724
Lead sponsor
Tianjin University of Traditional Chinese Medicine
Responsible party
Chunquan Yu (Director, Tianjin University of Traditional Chinese Medicine) — Principal investigator
First posted
Jul 19, 2019
Start date
Sep 1, 2019 (estimated)
Primary completion
Mar 1, 2020 (estimated)
Completion
Sep 1, 2020 (estimated)
Last update
Jul 22, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Heart Diseases→

Other studies from this sponsor

Tianjin University of Traditional Chinese Medicine

Start the discussion